A test which uses artificial intelligence (AI) to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment, according to a study published in Clinical Cancer Research. A team at the University of Leeds collaborated with researchers at Roche Diagnostics to develop the technique, which could help doctors and patients to decide on the best treatment options. They used samples from a previous trial funded by Cancer Research UK to look at the levels of two proteins, known as tumor amphiregulin (AREG) and epiregulin (EREG), which are produced by some colorectal cancers.